Streetbeat News

Earnings

MAX

MediaAlpha projects Q1 revenue to be between $105M-$115M, indicating a 1% year-over-year decline at the midpoint. The expected Q1 transaction value is forecasted to be $175m-$190m, showing a 6% decrease year-over-year at the midpoint. However, adjusted EBITDA is anticipated to be between $9.5 million and $11.5 million, marking a 45% increase year-over-year at the midpoint of the guidance range.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:44 pm

ENVX

Enovix Corp (NASDAQ:ENVX) reported Q4 revenue of $7.38 million, surpassing estimates of $3.37 million but had an adjusted loss of 28 cents per share, missing the expected loss of 27 cents. The company attributes its strong performance to Routejade and U.S. Army shipments. Enovix ended the quarter with $306.8 million in cash and investments, and aims to become a scale supplier with significant revenue and margins. For Q1, Enovix forecasts revenue between $3.5 million and $4.5 million, below estimates, and anticipates a larger loss per share than expected. Shares rose 5.94% after hours to $12.48.

Portfolio Pulse from Adam Eckert

February 20, 2024 | 9:43 pm

MED

MEDIFAST INC projects its Q1 2024 earnings per share (EPS) to be between $0.25 and $0.95, significantly below the estimated $1.50. The company also forecasts revenue to range from $155 million to $175 million, which is lower than the expected $205.786 million.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:42 pm

AROC

Archrock (NYSE:AROC) reported Q4 2023 earnings of $0.21 per share, meeting analyst estimates and marking a 200% increase from the previous year. Sales reached $259.59M, exceeding estimates by 2.21% and showing an 18.61% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:42 pm

AMPL

Amplitude has provided its financial outlook for FY24, expecting revenue to be between $291.5M and $294.5M, which is below the estimated $297.386M. The company also forecasts an adjusted EPS of $0.06 to $0.08, lower than the estimated $0.13.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:41 pm

GMED

Globus Medical (NYSE:GMED) reported Q4 2023 adjusted EPS of $0.60, missing the $0.61 estimate, but sales of $616.53M exceeded the $607.09M estimate. This represents a 1.69% increase in EPS and a 124.60% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:40 pm

HALO

Halozyme Therapeutics projects its FY24 adjusted EPS to be between $3.55 and $3.90, surpassing the estimated $3.51. The company also forecasts revenue to range from $915M to $985M, which brackets the estimated $961.088M.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:40 pm

CMTG

Claros Mortgage Trust (NYSE:CMTG) reported Q4 earnings with an EPS of $0.26, missing estimates by 7.14% and a revenue decrease of $7.64 million from the previous year. This follows a pattern of missed EPS estimates in previous quarters.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:40 pm

SEDG

SolarEdge Technologies, Inc. (NASDAQ:SEDG) reported mixed Q4 results with earnings beating analyst expectations but sales missing estimates and showing a significant year-over-year decrease. The company anticipates Q1 revenue to be between $175 million to $215 million, with the solar segment's gross margin expected to be 1% to 5%, factoring in a net IRA manufacturing tax credit. Shares dropped 17.5% in after-hours trading.

Portfolio Pulse from Erica Kollmann

February 20, 2024 | 9:40 pm

JBT

John Bean Techs (NYSE:JBT) reported Q4 earnings with an EPS of $1.4, beating estimates by 2.94% but with a revenue decrease of $154.50 million from the previous year. The company has a history of beating EPS estimates, which previously led to a 10.04% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:40 pm